vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and VALUE LINE INC (VALU). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $8.3M, roughly 1.8× VALUE LINE INC). On growth, VALUE LINE INC posted the faster year-over-year revenue change (-7.7% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs -4.1%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Value Line, Inc. is a publicly traded investment research and financial publishing firm based in New York City. Founded in 1931 by Arnold Bernhard, Value Line is best known for publishing The Value Line Investment Survey, a stock analysis newsletter that tracks approximately 1,700 publicly traded stocks.

IRIX vs VALU — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.8× larger
IRIX
$14.7M
$8.3M
VALU
Growing faster (revenue YoY)
VALU
VALU
+62.0% gap
VALU
-7.7%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
-4.1%
VALU

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
IRIX
IRIX
VALU
VALU
Revenue
$14.7M
$8.3M
Net Profit
$5.9M
Gross Margin
37.2%
Operating Margin
12.1%
Net Margin
71.4%
Revenue YoY
-69.7%
-7.7%
Net Profit YoY
14.5%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
VALU
VALU
Q1 26
$8.3M
Q4 25
$14.7M
$8.6M
Q3 25
$12.5M
$8.6M
Q2 25
$13.6M
$8.4M
Q1 25
$11.9M
$9.0M
Q4 24
$12.7M
$8.8M
Q3 24
$11.6M
$8.9M
Q2 24
$12.6M
$9.0M
Net Profit
IRIX
IRIX
VALU
VALU
Q1 26
$5.9M
Q4 25
$5.7M
Q3 25
$-1.6M
$6.5M
Q2 25
$-994.0K
$4.0M
Q1 25
$-1.7M
$5.2M
Q4 24
$-834.0K
$5.7M
Q3 24
$-1.9M
$5.9M
Q2 24
$-2.7M
$4.8M
Gross Margin
IRIX
IRIX
VALU
VALU
Q1 26
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Operating Margin
IRIX
IRIX
VALU
VALU
Q1 26
12.1%
Q4 25
17.7%
Q3 25
-11.3%
17.4%
Q2 25
-6.9%
9.9%
Q1 25
-1.7%
17.4%
Q4 24
-3.9%
19.7%
Q3 24
-16.1%
20.8%
Q2 24
-20.9%
16.5%
Net Margin
IRIX
IRIX
VALU
VALU
Q1 26
71.4%
Q4 25
66.4%
Q3 25
-12.6%
75.1%
Q2 25
-7.3%
47.1%
Q1 25
-14.2%
57.6%
Q4 24
-6.6%
64.3%
Q3 24
-16.7%
66.3%
Q2 24
-21.2%
53.1%
EPS (diluted)
IRIX
IRIX
VALU
VALU
Q1 26
Q4 25
Q3 25
$-0.09
Q2 25
$-0.06
Q1 25
$-0.10
Q4 24
$-0.05
Q3 24
$-0.12
Q2 24
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
VALU
VALU
Cash + ST InvestmentsLiquidity on hand
$6.0M
$92.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.8M
Total Assets
$29.2M
$151.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
VALU
VALU
Q1 26
$92.5M
Q4 25
$6.0M
$86.6M
Q3 25
$5.6M
$33.7M
Q2 25
$6.8M
$67.7M
Q1 25
$7.2M
$52.8M
Q4 24
$2.4M
$22.3M
Q3 24
$3.9M
$30.9M
Q2 24
$4.1M
$4.4M
Total Debt
IRIX
IRIX
VALU
VALU
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Stockholders' Equity
IRIX
IRIX
VALU
VALU
Q1 26
$107.8M
Q4 25
$105.5M
Q3 25
$4.7M
$103.0M
Q2 25
$6.1M
$99.7M
Q1 25
$852.0K
$99.0M
Q4 24
$2.1M
$96.7M
Q3 24
$2.6M
$93.9M
Q2 24
$4.2M
$90.8M
Total Assets
IRIX
IRIX
VALU
VALU
Q1 26
$151.0M
Q4 25
$29.2M
$147.9M
Q3 25
$28.4M
$148.2M
Q2 25
$31.6M
$144.5M
Q1 25
$34.2M
$143.6M
Q4 24
$29.1M
$140.0M
Q3 24
$30.2M
$138.6M
Q2 24
$31.2M
$136.0M
Debt / Equity
IRIX
IRIX
VALU
VALU
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
VALU
VALU
Operating Cash FlowLast quarter
$5.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
0.89×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
VALU
VALU
Q1 26
$5.3M
Q4 25
$3.0M
Q3 25
$-1.2M
$5.6M
Q2 25
$-397.0K
$20.2M
Q1 25
$-1.1M
$6.9M
Q4 24
$-1.2M
$3.1M
Q3 24
$-3.1M
$4.8M
Q2 24
$-1.3M
$17.9M
Free Cash Flow
IRIX
IRIX
VALU
VALU
Q1 26
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
$20.1M
Q1 25
$-1.2M
$6.8M
Q4 24
$-1.2M
$3.0M
Q3 24
$-3.1M
$4.8M
Q2 24
$17.9M
FCF Margin
IRIX
IRIX
VALU
VALU
Q1 26
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
239.2%
Q1 25
-9.8%
75.3%
Q4 24
-9.8%
34.1%
Q3 24
-26.5%
53.7%
Q2 24
199.0%
Capex Intensity
IRIX
IRIX
VALU
VALU
Q1 26
0.0%
Q4 25
0.0%
Q3 25
0.1%
0.0%
Q2 25
0.1%
2.1%
Q1 25
0.1%
1.2%
Q4 24
0.1%
0.7%
Q3 24
0.0%
0.0%
Q2 24
0.0%
0.2%
Cash Conversion
IRIX
IRIX
VALU
VALU
Q1 26
0.89×
Q4 25
0.52×
Q3 25
0.86×
Q2 25
5.12×
Q1 25
1.33×
Q4 24
0.54×
Q3 24
0.81×
Q2 24
3.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons